来源：公司公告 12月18日，航天智装（300455）公告称，公司于2025年11月13日至2025年12月11日在北京产权交易所公开挂牌 转让全资子公司航天轩宇（杭州）智能科技有限公司100%股权，挂牌价格以资产评估值1392.8万元为底价。公 司控股股东航天神舟投资管理有限公司作为唯一意向受让方，拟以挂牌底价受让杭州轩宇100%股权。 航天智装表示，此次转让是根据聚焦主业战略发展规划并结合实际经营情况而定。本次股权转让完成后，神舟 投资持有杭州轩宇的股权比例为100%，航天智装将不再持有杭州轩宇股权，杭州轩宇将不再纳入公司合并报表 范围。 关联关系方面，截至本公告披露日，神舟投资持有航天智装股份144,399,791股，占公司总股本的比例为 20.12%，为公司控股股东。根据《深圳证券交易所股票上市规则》有关规定，神舟投资为公司的关联法人，本 次交易构成关联交易。 据悉，此次交易的标的公司航天轩宇主营铁路货运巡检与核工业场景的特种机器人研发，公告显示，航天轩宇 2025年1月~7月，实现营业收入1133.05万元，利润总额-295.02万元，净利润-295.20万元。 与此同时，上市公司的业绩也遭遇了大幅 ...

格隆汇12月12日丨*ST长药(300391.SZ)公布，子公司河北羿珩科技有限责任公司(简称"羿珩科技")已于 近日停产。鉴于光伏行业目前的竞争环境及羿珩科技本身资金紧张、持续亏损的现状，为避免损失的进 一步扩大，降低运营成本，维护股东利益，羿珩科技近日决定实行停产，后续将根据市场等情况决定是 否恢复生产。 羿珩科技主要经营光伏产品，停产不会对公司医药产业正常生产经营活动产生不利影响。因羿珩科技目 前处于亏损状态，运营资金紧张，短时间内难以扭亏，羿珩科技停产将减少公司经营亏损，减少其对公 司业绩的负面影响，避免继续生产造成更大规模的亏损和资金投入，有利于降低运营成本，契合公司聚 焦医药产业的战略发展方向，符合公司和全体股东的利益，本次停产对公司经营数据的具体影响以经审 计的财务报告为准。公司已安排羿珩科技的高管团队坚守岗位、履职尽责，做好停产期间的相关处置工 作，维持羿珩科技稳定，依法保障羿珩科技现有资产安全和职工合法权益；已安排羿珩科技成立催收专 班，尽快催收货款，优先解决员工薪资拖欠问题。羿珩科技后续将根据市场等情况决定是否恢复生产运 营，并积极寻求对外合作机会，充分利用资产剩余使用价值，尽可能降低羿珩 ...

Core Viewpoint - Guosheng Financial Holding Group Co., Ltd. has officially changed its name to Guosheng Securities Co., Ltd., marking the establishment of Jiangxi's first listed securities firm through a merger with its wholly-owned subsidiary, Guosheng Securities [1][4][9]. Company Name Change and Business Focus - The company has completed the registration procedures for changing its name, registered address, and business scope, focusing solely on securities operations [6][8]. - The new business scope includes securities business, securities investment consulting, and public securities investment fund services, while non-financial businesses such as rubber manufacturing and cable production have been completely divested [6][7]. Leadership Changes - A new leadership team has been established, with Liu Chaodong elected as the new chairman and Zhao Jingliang appointed as the general manager [1][11][13]. - The board of directors has also appointed several vice presidents and other key management positions to strengthen the company's operational capabilities [11][13]. Financial Performance - For the first three quarters of the year, the company reported revenue of 1.856 billion yuan, a year-on-year increase of 46.84%, and a net profit of 242 million yuan, up 191.21% [2][19]. - In the third quarter alone, revenue reached 720 million yuan, a 78.17% increase year-on-year, but net profit decreased by 15% to 33 million yuan due to changes in accounting methods for equity investments [2][19]. Strategic Implications - The merger and name change are seen as a strategic move to enhance the company's focus on its core securities business and improve operational efficiency by reducing management layers [14][17]. - The company aims to leverage its status as Jiangxi's only fully licensed securities firm to deepen its market presence and brand recognition [4][14]. Market Position and Future Plans - Guosheng Securities is positioned as a national comprehensive securities company with a registered capital of 1.935 billion yuan and total assets of 48.8 billion yuan as of September 2025 [17]. - The company plans to apply for a change in its A-share stock name on the Shenzhen Stock Exchange and will continue to disclose information as necessary [8][19].

Core Insights - Fosun International reported a total revenue of RMB 87.28 billion for the first half of 2025, with a net profit attributable to shareholders of RMB 660 million [1] - The four core subsidiaries—Fosun Pharma, Yuyuan, Fosun Portugal Insurance, and Fosun Tourism—accounted for 73% of the group's total revenue, generating RMB 63.61 billion [1] - The company emphasized its strategic focus on innovation and globalization, leading to robust business development [1] Financial Performance - Fosun Pharma achieved a net profit of RMB 1.7 billion, marking a year-on-year increase of 38.96% [1] - Yuyuan's jewelry and fashion segment reported revenue of RMB 12.9 billion, with a significant quarter-on-quarter increase in Q2 [1] - Fosun Portugal Insurance's net profit reached EUR 133 million, reflecting a 27.6% year-on-year growth [1] - Fosun Tourism's revenue hit a record high of RMB 9.53 billion, with an adjusted net profit growth of 42.0% [1] Innovation and R&D - The company invested RMB 3.6 billion in innovation, with several breakthroughs in innovative drugs, including the approval of a new drug for rare tumors [2] - The potential total for the overseas authorization of a small molecule oral DPP-1 inhibitor is USD 645 million [2] - The PD-L1 targeted ADC HLX43 has entered global Phase II clinical trials, showing significant competitive advantages [2] - The innovative anti-HER2 monoclonal antibody HLX22 became the first globally to receive orphan drug designation in both the EU and the US for gastric cancer [2] Global Operations - Fosun's overseas revenue reached RMB 46.67 billion, accounting for 53% of total revenue, with a significant increase in profits from overseas products [2] - The overseas product profits of Fosun Pharma surged over 200%, with expectations for substantial growth in 2025 and continued high growth in 2026 [2] Market Outlook - Club Med's global performance reached a new high with revenue of RMB 9.25 billion and an operating profit of RMB 1.27 billion, reflecting an 11.0% year-on-year growth [3] - The company maintains a healthy debt-to-capital ratio of 53%, with a stable outlook confirmed by S&P [3] - The chairman highlighted the successful execution of the core business strategy, particularly in the pharmaceutical and health sectors, and the commitment to creating greater value for shareholders and society [3]